- Press Release -

Rockville, Md. The global peptide based cardiovascular therapeutics market is set to reach nearly US$ 1.96 Bn by 2022 on robust growth, according to Fact.MR. Once held back by low stability, quick degradation and poor delivery, therapeutic peptides for cardiovascular disease are gaining ground as more R&D funding opens new avenues and breakthroughs improve peptide design.

Eptifibatide leads by drug, retail pharmacies carry the largest share, and North America, led by the United States, dominates demand.

Drugs, Channels and Regions

Eptifibatide is the leading drug, reaching nearly US$ 600 Mn by 2022 at about a third of revenue and gaining share. On distribution, retail pharmacies hold more than a third of revenue and gain ground. North America reaches nearly US$ 830 Mn by 2022, with the United States alone accounting for about 88.6% of global revenue in 2017 and gaining further share.

Disease Burden Drives Demand

The market runs on clinical need and investment. A growing number of people with cardiovascular disease, higher healthcare spending, and rising foreign investment in emerging economies are lifting demand, while the cost of developing peptides, their rapid metabolism and a strict regulatory framework temper faster growth.

Suppliers and Their Playbook

The field brings together specialty and large pharmaceutical companies.

• Amneal Pharmaceuticals LLC, Fresenius Kabi USA, LLC, Corden Pharma GmbH, AstraZeneca, plc, Novetide Ltd, Pfizer Inc, Dr. Reddy's Laboratories Limited, Ipsen S.A, Apotex Holdings, Inc., and Merck & Co. are among the key players in the report.

Reading the Market for Decisions

For drug makers, growth favours continued peptide development and portfolio expansion. Investors get a market with robust, disease-led demand concentrated in the United States. Procurement and pharmacy teams can plan around eptifibatide carrying volume, retail pharmacies leading distribution, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global peptide based cardiovascular therapeutics market for the 2017 to 2022 forecast period, with segmentation by drug, distribution channel and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the peptide based cardiovascular therapeutics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.